BIO-SFJune 8, 2016

NEMUS BioscienceOTCQB: NMUS

2

Forward Looking Statement

This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions ofthe Private Securities Litigation Reform Act of 1995. All of the statements in this presentation, whether written ororal, that refer to expected or anticipated future actions and results of NEMUS Bioscience, Inc. (NEMUS) areforward-looking statements. These forward-looking statements reflect the beliefs and expectations of themanagement of NEMUS as of the date of this presentation. NEMUS cannot give any assurance that such forward-looking statements will prove to be correct. The reader is cautioned not to place undue reliance on these forward-looking statements.

The information provided in this presentation does not identify or include any risk or exposures, of NEMUS thatwould materially adversely affect the performance or risk of the company. For a description of the risks anduncertainties related to the business of NEMUS, see our Annual Report on Form 10-K filed with the Securities andExchange Commission and our subsequent periodic reports filed with the Securities and Exchange Commission.

All information contained in this presentation is provided as of the date of the presentation and is subject tochange without notice. Neither NEMUS, nor any other person undertakes any obligation to update or revisepublicly any of the forward-looking statements set out herein, whether as a result of new information, futureevents or otherwise, except as required by law. This presentation does not convey an offer of any type and is notintended to be, and should not be construed as, an offer to sell, or the solicitation of an offer to buy, any securitiesof NEMUS.

3

OTCQB NMUS

Price (6/7/16) $0.46

Market Cap (3/15/16) $9.2 M

Shares Outstanding19.9 M common & 4500 PS,25.5 M if 100% converted

% Ownership by Directors & Employees

31.4% shares1.2 M options

Warrants Outstanding 10.9 M (Avg. Strike @ $1.15)

Founded 2012

Base of OperationsCosta Mesa, California & Oxford, Mississippi

Company Overview

NEMUS Bioscience is a publicly traded, life-science biotech company, focused on developing regulatory-approved, cannabinoid-based therapies, for a

spectrum of diseases, especially those of unmet medical need

4

NEMUS Value Proposition

• NEMUS is focused on developing cannabinoid molecules for the treatment and management of acute and chronic diseases, especially those of unmet medical need

• NEMUS is the sole development and commercialization partner of the University of Mississippi, drawing on 48 years of intellectual capital in cannabinoid chemistry and physiology from the only entity with a Federal license to directly study cannabinoids

• NEMUS is advancing therapeutics for medical applications in global multi-billion dollar markets including:

A cannabinoid franchise in ophthalmology in glaucoma and retinal diseases

Palliative care in oncology (CINV and CIPN)

Anti-infectives, especially in strains developing resistance to antibiotics (MRSA)

• Proprietary product pipeline led by a pro-drug of tetrahydrocannibinol (THC) and novel derivatives of cannabidiol (CBD)

• NEMUS management team has proven track-record in drug research, pharmaceutical & biotech development, and public company experience on a global scale

5

NEMUS Milestones

Recent Milestones

• August 2015: Completion of Series B $5 million financing round

• October 2015: Patent issued in Japan for NB1111 (THC prodrug)

• December 2015: NEMUS in-licenses CBD derivatives from UM and initiates research into chemotherapy induced peripheral neuropathy (CIPN)

• January 2016: NEMUS announces validation of NB1111 data in glaucoma with 45% decline in IOP as NEMUS becomes leading cannabinoid drug developer in ophthalmology

• January 2016: NEMUS announces initiation of development program for chemotherapy-induced nausea and vomiting (CINV) and pre-NDA meeting with the FDA

• February 2016: NEMUS signs agreement with AMRI to manufacture proprietary API for glaucoma (NB1111) and CINV (NB1222) programs

• June 2016: NEMUS announces successful identification of CBD-like candidate molecule (NB2111) with significant analgesic activity versus morphine in validated animal CIPN study; program advancing into pre-clinical phase

6

NEMUS Cannabinoid Prodrug Programs Hold Competitive Advantages

Orally administered cannabinoids (both pill and spray delivery mechanisms) hold a variety of disadvantages for patients:

• Poor bioavailability vs other routes of administration

• Irregular pharmacokinetics secondary to GI absorption

• Susceptible to significant first-pass metabolism by the liver

– “Due to extensive first-pass metabolism and high lipid solubility, a fraction of the drug reaches the circulation”1

– “The pharmacologic effects of Marinol are dose-related and subject to considerable inter-patient variability”1

– “Intoxication type reactions appear dose-related due to great inter-patient drug level variability” 2

– “The pharmacokinetic data show great inter-subject variability”3

1) Marinol Summary Basis of Approval2) Sativex Product Labelling - Black Box Warning3) Sativex Product Labelling

NEMUS prodrug technology designed to capitalize on the use of proprietary formulations that could allow for alternative delivery methods mitigating risk of unpredictable plasma levels that can compromise safety and efficacy

7

Innovative Cannabinoid Formulations Designed for Improved Drug Delivery

-

• Ocular delivery: Glaucoma & retinal diseases

• Transmucosal delivery: CINV & CIPN (suppository & buccal patch)

• Transmembranous delivery: Anti-infectives (Anti-MRSA)(nasal/transdermal)

All NEMUS licensed delivery options optimize our prodrug cannabinoid technology by enhancing bioavailability by avoiding

first-pass liver metabolism and offering more predictable pharmacokinetics

8

• The University of Mississippi (UM) is the only entity in the US authorized by NIDA and the DEA to cultivate cannabis on behalf of the federal government

• The University of Mississippi has a continuous 45+ year regulatory history in dealing with FDA, DEA, NIDA, NIH, etc.

• NEMUS has exclusive, perpetual, worldwide exclusivity for all compounds and targets we are working on with UM for key fields of delivery

• NEMUS has:

• Recurring option agreements for unique THC and CBD derivative molecules including patent 8,809,261 issued August, 2014 covering NCE of cannabinoid prodrug esters

• Multiple method of delivery agreements including ocular, transmembranous, transmucosal

• Multiple research agreements including CIPN and MRSA

The Only Federally-Approved Source of Cannabis-Derived Compounds

9

Development Pipeline: Optimizing THC and CBD Delivery Through Unique Formulations

Drug Name Target Delivery Research Pre-clinical Phase 1Phase

2/3

NB1222(THC-based)

Chemotherapy-induced nausea & vomiting (CINV)

Suppository & Buccal Patch

NB1111(THC-based)

Glaucoma/Ophthalmology Targets

Sustained Ocular

NB2111(CBD-based)

Chemotherapy-induced peripheral neuropathy (CIPN)

Trans-membranous

ID pending Methicillin-Resistant Staph Aureus (MRSA)

Topical &Transdermal

Target indications are multi-billion dollar global markets of urgent medical need

10

NB1222Treatment of

Chemotherapy-Induced Nausea and Vomiting (CINV)

11

NB1222: Chemotherapy-Induced Nausea and Vomiting (CINV)

• There are an estimated 15 million cancer cases globally according to the International Agency for Research on Cancer

• 25%-30% of patients receive chemotherapy; of the chemotherapy recipients, 70%-80% experience CINV

• The global CINV market exceeds $1.3 B

• Dronabinol is an orally administered synthetic version of THC approved for cachexia in HIV and nausea/vomiting in CINV with annual sales for CINV in excess of $110 MM (Source: IMS Health)

• NEMUS plans to initially develop a suppository version of our proprietary prodrug of THC, NB 1222, for use in CINV by filing an NDA via the expedited regulatory pathway of 505(b)(2)

12

NB1222 Advantages Versus Dronabinol in CINV

-1

4

9

PD 1 3 5 7 9 11 13 15 17 19 21 23

Pla

sma

Co

nce

ntr

atio

ns

(ng/

ml)

Timepoint (h)

A Comparison of THC Plasma Concentrations From ProDrug THC Suppository* vs. dronabinol in Humans

Dronabinol 10 mg THC 10 mgEg

• Bioavailability: Dronabinol has been found to have a bioavailability of 6%-15% while a prodrug of THC administered via suppository yielded a bioavailability of roughly 70%*

• Absorption: Orally administered dronabinol can have erratic absorption from the gut coupled to varying plasma levels due to first-pass metabolism in the liver; a suppository avoids the upper GI tract and thereby de-risks the negative effect of first-pass metabolism on the drug pharmacokinetics

• Adverse Events: Oral dronabinol has been associated with nausea and vomiting adverse events; a suppository route of administration mitigates that side effect

• Pharmacokinetics: THC prodrug dosing using a suppository allows greater drug exposure (graph above) and maintenance within the therapeutic window versus peak/trough PK with oral dosing

Source: NEMUS Internal Data

13

NB1111For the Treatment of

Glaucoma

14

Visual Field Defect in GlaucomaHow the World is Seen With Glaucoma

15

The Glaucoma Market

• $8 billion globally and growing with aging populations

• A leading cause of blindness in the US

• $2.3 billion US market (32 MM Rx)

• Regulatory pathway well-defined

• Regulatory strategy: Potential for “urgent medical need” and “breakthrough therapy” FDA designations;

• Glaucoma as a “Non-responder” market presents greater opportunities; >50% of patients on 2 or more Rx

• Cannabinoids have shown neuroprotective qualities in vitro and in vivo (multiple animal species)

• Licensing and acquisitions in the glaucoma market occur predominantly earlier in development (pre-clin, phase 1)

16

NB1111 (Glaucoma/Ophthalmology)

Sustained release treatment with a proprietary THC prodrug could bring a new therapeutic class directly to the target organ, avoiding systemic exposure

OCULAR FEATURES OF NB1111

• Penetrates all chambers of the eye

• Produces a 45% reduction in Intra-Ocular Pressure (IOP) in glaucoma animal model (THC has been shown to lower IOP in previous human testing)

• Reduction of IOP is the only proven method to treat glaucoma

• Sustained release via implantable delivery vehicle enhance compliance

• Potentially first medication to exert direct neuroprotection of the optic nerve (retinal ganglion cells; RGCs) by inhibiting apoptosis pathway

• Neuroprotection is the “holy grail” of glaucoma

The proprietary formulation allows THC to be absorbed across membranes that are normally barriers to absorption

17

THC Lowers IOP in Humans; Predictive Animal Model Consistent with Human Experience

• The active moiety of NB1111, THC, has been shown to lower IOP in multiple human studies • THC delivered by inhalation (smoking) or edible lowered IOP 40% to 65% but

compromises blood flow to retina via systemic vasodilation and dosing complicated by short half-life

• The NEMUS prodrug NB1111 achieved a 45% reduction in IOP in validated rabbit glaucoma model testing conducted at UM

• New formulation testing of NB1111 will confront the compliance issue of topical drops (eyedrops) by development of implantable sustained release device

• Next stage testing:• Human studies looking at IOP lowering effect as single dose and multi-

dosages

• In vitro and in vivo studies assessing neuroprotective biomarkers

18

THC Can Address Multiple MOAs in Lowering IOP and Preserving Retinal Ganglion Cells (RGCs)

Therapy Class

Mechanism ofAction (MOA)

Increased flow trabecular mesh

Increased flow uveoscleral

pathwayDecreased fluid

production

Directneuroprotective

qualities

Prostaglandins (50% mkt share)

X

β- adrenergic blockers (30%)

X

α- adrenergicagonists (10%)

X X

Carbonic anhydrase inhibitors (<5%)

X

Cholinergic agonists (<5%)

X

Pro-drug THC(NB1111)

X X X X

19

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)

CBD DERIVATIVES

20

Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market Data

• CIPN is a dose-dependent complication associated with many types of chemotherapeutic agents

• In addition to severe, sometimes unremitting pain, it can also lead to premature discontinuation of chemotherapy which in turn can compromise responses to cancer treatment

• No agents have been shown to prevent CIPN and currently there is a significant unmet medical need for therapies that can mitigate the pain without complications associated with addiction and gastrointestinal obstruction

• The CIPN market in the United States exceeds $500 MM (LifeSci Advisors, 2013) and the parallel opioid-induced constipation market is estimated to be $600 MM globally (GlobalData, 2015)

• The overall global pain market is projected to be $35 billion by 2017*

* GBI Research: Global Pain Markets, 2015

21

NB2111: exhibits significant analgesia

• NEMUS has signed a research agreement with UM to test CBD-related derivatives in validated animal models of CIPN; research to date has identified both pro-drugs and analogues of CBD

• NB2111 is a CBD-like molecule that has been tested in a rodent model of tactile allodynia replicating the neuropathy associated with exposure to the chemotherapeutic agent of cisplatin

• NB2111 resulted in significant analgesia in this model with coverage commensurate with that seen using the highest dose of morphine exposure

• Next steps in development include advancing the testing to assess maximum tolerable dose in animal studies and developing the formulation of the compound to make it suitable for parenteral and non-parenteral dosing

• NEMUS and UM will continue assessing other forms of CBD derivatives in an effort to develop therapeutic options for multiple types of pain syndromes and possible anti-addictive uses to combat the global opioid addiction crisis

22

METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

MULTIPLE CANNABINOIDDERIVATIVES

23

MRSA Has Become a Global Urgent Health Concern

24

Methicillan-Resistant Staph Aureus (MRSA)

MRSA FACTS & CURRENT MEDICAL LANDSCAPE

• First described in 1961 now a pandemic

• CDC: prevalence of MRSA in ICU setting approaching 60%

• 1960’s: one genetic MRSA mutation/clone; currently six MRSA genetic clones; 15 clones in China

• 2010 hospital survey: 61.8% of patients admitted to ICU were MRSA colonized1

• 50% of screened patients had healthcare-associated infections1

• 11,000 deaths annually; 80,000 invasive infections/yr.2

• Annual costs in the US: $3.2 - $4 billion2

1) Jarvis WR et al; Am J Infect Control 2012; 40(3): 194-2002) Pew Trust MRSA Survey; April 3, 2012

25

Methicillan-Resistant Staph Aureus (MRSA)

NEMUS is Assessing a New Class of Anti-Infectives to Combat the Threat of Antibiotic Resistance

CANNABINOID EXPERIENCE IN MRSA1

• Select cannabinoids have been known to possess some antibacterial properties 1

• Anti-bacterial properties can be leveraged to address newly developed strains exhibiting antibiotic resistance to current meds

• NEMUS intends to seek IP protection concerning the use of transmembrane enhancing formulations of cannabinoids to facilitate bacteriocidal activity

• A spectrum of gram-positive organisms will be screened in addition to MRSA

1) J Nat Prod. 2008 Aug;71(8):1427-30. doi: 10.1021/np8002673. Epub 2008 Aug 6. - Antibacterial cannabinoids from Cannabis sativa: a structure-activity study

26

NEMUS Bioscience, Inc. (OTCQB: NMUS)

• NEMUS is focused on developing cannabinoid molecules for the treatment and management of acute and chronic diseases, especially those of unmet medical need

• NEMUS cannabinoid molecules are engineered to enhance trans-membrane transport resulting in: Enhanced bioavailability Permits routes of administration that avoid first-pass metabolism by the liver Resulting in more predictable pharmacokinetics Patent issued in August, 2014 allows long IP runway with broad claims and reach for

the delivery of molecules and conditions that can be treated

• NEMUS is the sole development and commercialization partner of the University of Mississippi, drawing on 47 years of intellectual capital in cannabinoid chemistry and physiology

• NEMUS is advancing therapeutics for medical applications in global multi-billion dollar markets including a cannabinoid franchise in ophthalmology, palliative care in oncology, and anti-infective medicines, especially in strains developing resistance to antibiotics

27

Management

BRIAN MURPHY, MD, MPH, MBA – Chief Executive Officer; Chief Medical Officer, DirectorDr. Murphy has almost two decades of experience in drug development and evaluation, both from the academic and industryperspective. He most recently served as the CMO of Eiger Biosciences. Previously, Dr. Murphy was CMO at ValeantPharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs andPharmacovigilance. Dr. Murphy also served as Medical Director, then VP of Marketing and Commercial Strategy of Hepatologyfor InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons atHoffmann-LaRoche. Murphy is board-certified in internal medicine and completed his residency at Tufts-New England MedicalCenter. He went on to complete parallel fellowship tracts at Harvard Medical School and the Massachusetts General Hospital.Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and isa graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the ColumbiaUniversity Graduate School of Business.

LIZ BERECZ, MA, CPA - Chief Financial OfficerElizabeth Berecz is a seasoned financial executive with over 20 years of experience holding senior level positions in both privateand public companies. She has proven success in leading strategic planning, financial reporting, and global systemimplementations for companies of various sizes. Liz started her career at Price Waterhouse Silicon Valley where she spent fiveyears auditing several high profile public companies in the technology industry. She then spent 10 years holding key leadershippositions in various publicly held Companies including Quantum Corporation (Corporate Controller), Business Objects (VPFinance and Administration), and Excite (VP Finance), followed by 10 years of key leadership roles in privately held Companiesincluding CFO positions with Optical Shop International, StarTrac Inc., Power Balance Technologies, Inc. and most recentlyBentley Mills, Inc. She also serves as an Adjunct Professor of Accounting and Finance at the University of San Francisco.Elizabeth received her BA in Economics from Stanford University and a MA in Sports Management from University of SanFrancisco.

28

Management

COSMAS N. LYKOS, ESQ – Co-founder, Officer & Board Member – Executive Chairman Cosmas Lykos co-founded NEMUS in 2012 and has served as its Chairman of the Board of Directors since August2014. After graduating with Honors from Duke University School of Law in 1993, Mr. Lykos began his career at GibsonDunn & Crutcher, LLP, an international full-service law firm, as a corporate associate until 1998. From 1998 to 2004, Mr.Lykos served as Vice President of Business Affairs, General Counsel, Secretary and Chief Compliance Officerof RemedyTemp, Inc., a NASDAQ publicly-traded temporary staffing firm with over 250 directly-owned and franchisedoffices nationwide. From 2004 until 2008, Mr. Lykos served as Vice President of Business Development, Chief Legal Officer,Secretary and Chief Compliance Officer of Oakley, Inc., a NYSE publicly-traded sports and technical eyewear, apparel,accessories and retail company. In January of 2008, he became Co-owner and President of the Optical Shop International,a designer and distributor of licensed eyewear brands, including Chrome Hearts and Blinde, through two wholly-ownedforeign subsidiaries with a direct and distributor sales network in over 60 countries around the world. Primaryresponsibilities included developing and implementing OSI’s vision and strategies and the management of its foreignsubsidiaries, sales, legal, human resources, finance and administrative functions. In 2011, Mr. Lykos negotiated andconsummated the sale of OSI to its primary licensor, Chrome Hearts LLC and continues to provide consulting services. Mr.Lykos has extensive public and private company board of directors experience. As Chief Compliance and Legal Officer andSecretary of both Oakley, Inc. and RemedyTemp, Inc., Mr. Lykos attended all board of director meetings and boardcommittee meetings. As an angel investor, Mr. Lykos has made minority investments in various private companies and hasserved on their Board of Directors.

29

BOD & Strategic Advisors

MAHMOUD A. ELSOHLY, PHD Scientific AdvisorWorld’s foremost expert on the science of cannabinoids. 300+ scientific publications . Research professor at The University of Mississippi.

JERRY MCLAUGHLIN, MBA Strategic Advisor, Board of Directors - MemberCEO of AgeneBio; 25 year veteran executive in pharmaceutical medical device and healthcare related industries (Endo Pharma, Merck, MBA- Villanova University,BA- Dickinson College).

TOM GEORGEBoard of Directors – Chairman of Audit Committee30 year senior executive in corporate finance and accounting; CFO of Deckers Brands ( Ophthonix, Oakley, Coopers & Lybrand). Graduate of University of Southern California.

DOUGLAS S. INGRAM, ESQBoard of Directors – Vice Chairman, Chairman of Compensation Committee25 year senior executive in healthcare, Past President of Allergan, former Attorney at Gibson, Dunn & Crutcher, LLP. Summa cum laude and Order of the Coif graduate of the Univ. of Arizona school of law.

ROBERT N. WEINREB, M.D. Scientific AdvisorChair, Ophthalmology Advisory BoardGlobally recognized expert on glaucoma and eye diseases. 1000+ scientific publications. Distinguished Professor of Ophthalmology; University of California San Diego.

DONALD I. ABRAMS, M.D. Scientific AdvisorChief, Hematology/Oncology at UCSFCancer and Integrative Medicine specialist with research interests in the development of anti-cancer therapeutics and palliative care medicines.

30

Contact

650 Town Center Drive, Suite 1770Costa Mesa, CA 92626

949-396-0330hello@nemusbio.com

www.nemusbioscience.com

Investor Relations:Adam HoldsworthPCG Advisory GroupTel: 646-862-4607adamh@pcgadvisory.com

Company:Brian Murphy, MD, MPH, MBACEO - CMOTel: 949-355-1140brian@nemusbio.com